BioSyent Inc. (CVE:RX) Senior Officer Robert Joseph March Sells 4,775 Shares

BioSyent Inc. (CVE:RX) Senior Officer Robert Joseph March sold 4,775 shares of BioSyent stock in a transaction on Thursday, December 12th. The shares were sold at an average price of C$11.65, for a total transaction of C$55,628.75.

BioSyent Stock Down 0.8 %

RX stock opened at C$11.61 on Friday. The company has a current ratio of 6.13, a quick ratio of 6.91 and a debt-to-equity ratio of 3.19. BioSyent Inc. has a 1 year low of C$8.24 and a 1 year high of C$11.74. The company has a fifty day simple moving average of C$11.19 and a 200 day simple moving average of C$10.51. The firm has a market cap of C$134.56 million, a PE ratio of 19.35 and a beta of 0.93.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.